Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Lymphoma
•
Myeloma
•
Hematology
What would your next line of therapy be for a young patient with Waldenstrom's Macroglobulinemia (MYD88 and CXCR wild type) with hyperviscosity who did not have a response to Bendamustine/Rituximab?
Related Questions
How should one approach advanced stage EBV+ DLBCL, NOS with concomitant HLH?
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
How would you treat cold agglutinin disease secondary to underlying marginal zone lymphoma with only bone marrow involvement and no disease elsewhere?
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
What is your standard approach to treatment of plasmablastic lymphoma in HIV negative patients?
